Endoscopic treatment: The past, the present and the future

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 4, 2014, Pages 685-702

  Mathus Vliegen, E M H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Aspire bariatrics system; Botulinum toxin A; Duodenojejunal bypass liner; Duodenojejunal bypass sleeve; Endoscopy; Gastric bubble; Gastric stapling; Gastric suturing; Intragastric balloons

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; ASPIRATION; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; BODY MASS; COMORBIDITY; DIET RESTRICTION; DIET THERAPY; DIGESTIVE IMPLANT; DIGESTIVE SURGICAL EQUIPMENT; DISEASE ASSOCIATION; DUODENOJEJUNAL BYPASS LINER; DUODENOJEJUNAL BYPASS SLEEVE; EATING DISORDER; ENDOLUMINAL VERTICAL GASTROPLASTY; ENDOSCOPE; ENDOSCOPIC BYPASS; ENDOSCOPIC THERAPY; ENERGY RESTRICTED DIET; EXERCISE; GASTRIC BALLOON; GASTRIC SLEEVE; GASTRIC STAPLING; GASTRIC SUTURING; GASTROENTEROLOGIST; GASTROINTESTINAL TRACT; GASTROPLASTY; HUMAN; MALABSORPTION; NONHUMAN; OBESITY; POSTOPERATIVE COMPLICATION; PRIMARY OBESITY SURGERY ENDOLUMENAL; PROSTHESIS; SLEEVE GASTRECTOMY; STAPLER; STOMACH BYPASS; STOMACH DISTENSION; STOMACH EMPTYING; STOMACH ULCER; SURGICAL STAPLING; SUTURE DELIVERY DEVICE; SUTURING METHOD; TRANSORAL GASTRIC VOLUME REDUCTION; TRANSORAL GASTROPLASTY; ASPIRE BARIATRICS SYSTEM; ENDOSCOPY; GASTROSCOPY; INTRAGASTRIC BALLOONS; REVIEW;

ASPIRE BARIATRICS SYSTEM; BOTULINUM TOXIN A; DUODENOJEJUNAL BYPASS LINER; DUODENOJEJUNAL BYPASS SLEEVE; ENDOSCOPY; GASTRIC BUBBLE; GASTRIC STAPLING; GASTRIC SUTURING; INTRAGASTRIC BALLOONS;

BARIATRIC SURGERY; GASTROSCOPY; HUMANS; OBESITY;

EID: 84909996028     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.07.009     Document Type: Review

References (110)

1. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: Report of a WHO Consultation on Obesity; 3-5 June 1997. Report 1998 No.: WHO/NUT/NCD/98.1.
2. National Institutes of Health, National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults- the evidence report. Obes Res 1998;6(Suppl. 2). 1S-209S.
3. National Institute of Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children; 2006. www.NICE.org.uk/CG43.
4. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013;23:427-36.
5. Tsesmeli N, Coumaros D. The future of bariatrics: endoscopy, endoluminal surgery, and natural orifice transluminal endoscopic surgery. Endoscopy 2010;42:155-62.
6. Abu Dayyeh BK, Thompson CC. Obesity and bariatrics for the endoscopist: new techniques. Ther Adv Gastroenterol 2011;4:433-42.
7. Delegge MH. Endoscopic approaches for the treatment of obesity: fact or fiction? Nutr Clin Pract 2011;26:534-8.
8. Espinet-Coll E, Nebreda-Duran J, Gomez-Valero JA, Munoz-Navas M, Pujol-Gebelli J, Vila-Lolo C, et al. Current endoscopic techniques in the treatment of obesity. Rev Esp Enferm Dig 2012;104:72-87.
9. Singhal S, Le DL, Duddempudi S, Anand S. The role of endoscopy in bariatrics: past, present, and future. J Laparoendosc Adv Surg Tech A 2012;22:802-11.
10. Thompson CC. Endoscopic therapy of obesity: a new paradigm in bariatric care. Gastrointest Endosc 2010;72:505-7.
11. Ginsberg GG, Chand B, Cote GA, Dallal RM, Edmundowicz SA, Nguyen NT, et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc 2011;74:943-53.
12. Frank BB, Stern WR, Fisher AH. Survey of gastric bubble usage in the United States. Rockville, MD: Fisher; 1987.
13. Schapiro M, Benjamin S, Blackburn G, Frank B, Heber D, Kozarek R, et al. Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19-21, 1987. Gastrointest Endosc 1987;33: 323-7.
14. Ello-Martin JA, Ledikwe JH, Rolls BJ. The influence of food portion size and energy density on energy intake: implications for weight management. Am J Clin Nutr 2005;82(Suppl. 1):236S-41S.
15. Geliebter A, Westreich S, Gage D. Gastric distention by balloon and test-meal intake in obese and lean subjects. Am J Clin Nutr 1988;48:592-4.
16. Geliebter A, Melton PM, McCray RS, Gage D, Heymsfield SB, Abiri M, et al. Clinical trial of silicone-rubber gastric balloon to treat obesity. Int J Obes 1991;15:259-66.
17. Mathus-Vliegen EMH, de Groot GH. Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity. Obes Surg 2013;23:622-33.
18. Mathus-Vliegen EM, Eichenberger RI. Fasting and meal-suppressed ghrelin levels before and after intragastric balloons and balloon-induced weight loss. Obes Surg 2014;24:85-94.
19. Tosetti C, Corinaldesi R, Stanghellini V, Pasquali R, Corbelli C, Zoccoli G, et al. Gastric emptying of solids in morbid obesity. Int J Obes Rel Metab Dis 1996;20:200-5.
20. Bonazzi P, Petrelli MD, Lorenzini I, Peruzzi E, Nicolai A, Galeazzi R. Gastric emptying and intragastric balloon in obese patients. Eur Rev Med Pharmacol Sci 2005;9(5 Suppl. 1):15-21.
21. Mion F, Napoleon B, Roman S, Malvoisin E, Trepo F, Pujol B, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg 2005;15:510-6.
22. Mion F, Gincul R, Roman S, Beorchia S, Hedelius F, Claudel N, et al. Tolerance and efficacy of an air-filled balloon in non-morbidly obese patients: results of a prospective multicenter study. Obes Surg 2007;17:764-9.
23. Martinez-Brocca MA, Belda O, Parejo J, Jimenez L, del VA, Pereira JL, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg 2007;17: 649-57.
24. Dogan UB, Gumurdulu Y, Akin MS, Yalaki S. Five percent weight lost in the first month of intragastric balloon treatment may be a predictor for long-term weight maintenance. Obes Surg 2013;23:892-6.
25. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005;61:19-27.
26. Geliebter A, Schachter S, Lohmann-Walter C, Feldman H, Hashim SA. Reduced stomach capacity in obese subjects after dieting. Am J Clin Nutr 1996;63:170-3.
27. Pappas TN. Physiological satiety implications of gastrointestinal antiobesity surgery. Am J Clin Nutr 1992;55:571S-2S.
28. Fernandes M, Atallah AN, Soares BG, Humberto S, Guimaraes S, Matos D, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev 2007;1:CD004931.
29. Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis 2008;26:40-4.
30. Dumonceau JM. Evidence-based review of the bioenterics intragastric balloon for weight loss. Obes Surg 2008;18: 1611-7.
31. Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, Sendra-Gutierrez JM, Gonzalez-Enriquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg 2008;18:841-6.
32. Genco A, Cipriano M, Bacci V, Cuzzolaro M, Materia A, Raparelli L, et al. BioEnterics Intragastric Balloon (BIB): a shortterm, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond) 2006;30:129-33.
33. Rossi A, Bersani G, Ricci G, Petrini C, DeFabritiis G, Alvisi V. Intragastric balloon insertion increases the frequency of erosive esophagitis in obese patients. Obes Surg 2007;17:1346-9.
34. Hirsch DP, Mathus-Vliegen EM, Holloway RH, Fakhry N, D'Amato M, Boeckxstaens GE. Role of CCK(A) receptors in postprandial lower esophageal sphincter function in morbidly obese subjects. Dig Dis Sci 2002;47:2531-7.
35. Hirsch DP, Mathus-Vliegen EM, Dagli U, Tytgat GN, Boeckxstaens GE. Effect of prolonged gastric distention on lower esophageal sphincter function and gastroesophageal reflux. Am J Gastroenterol 2003;98:1696-704.
36. Puglisi F, Antonucci N, Capuano P, Zavoianni L, Lobascio P, Martines G, et al. Intragastric balloon and binge eating. Obes Surg 2007;17:504-9.
37. Busetto L, Enzi G, Inelmen EM, Costa G, Negrin V, Sergi G, et al. Obstructive sleep apnea syndrome in morbid obesity: effects of intragastric balloon. Chest 2005;128:618-23.
38. Melissas J, Malliaraki N, Papadakis JA, Taflampas P, Kampa M, Castanas E. Plasma antioxidant capacity in morbidly obese patients before and after weight loss. Obes Surg 2006;16:314-20.
39. Ricci G, Bersani G, Rossi A, Pigo F, De FG, Alvisi V. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg 2008;18:1438-42.
40. Forlano R, Ippolito AM, Iacobellis A, Merla A, Valvano MR, Niro G, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc 2010;71:927-33.
41. Musella M, Milone M, Bellini M, Fernandez ME, Fernandez LM, Leongito M, et al. The potential role of intragastric balloon in the treatment of obese-related infertility: personal experience. Obes Surg 2011;21:426-30.
42. Fuller NR, Pearson S, Lau NS, Wlodarczyk J, Halstead MB, Tee HP, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obes (Silver Spring) 2013;21:1561-70.
43. Genco A, Bruni T, Doldi SB, Forestieri P, Marino M, Busetto L, et al. BioEnterics intragastric balloon: the italian experience with 2, 515 patients. Obes Surg 2005;15:1161-4.
44. Herve J, Wahlen CH, Schaeken A, Dallemagne B, Dewandre JM, Markiewicz S, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg 2005;15:864-70.
45. Dastis NS, Francois E, Deviere J, Hittelet A, Ilah MA, Barea M, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy 2009;41:575-80.
46. Crea N, Pata G, Della CD, Minelli L, Maifredi G, Di BE, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg 2009;19:1084-8.
47. Kotzampassi K, Grosomanidis V, Papakostas P, Penna S, Eleftheriadis E. 500 intragstraic balloons: what happen 5 years thereafter? Obes Surg 2012;22:896-903.
48. Pasulka PS, Bistrian BR, Benotti PN, Blackburn GL. The risks of surgery in obese patients. Ann Intern Med 1986;104: 540-6.
49. Gottig S, Weiner RA, Daskalakis M. Preoperative weight reduction using the intragastric balloon. Obes Facts 2009; 2(Suppl. 1):20-3.
50. Busetto L, Segato G, DeLuca M, Bortolozzi E, MacCari T, Magon A, et al. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study. Obes Surg 2004;14:671-6.
51. Frutos MD, Morales MD, Lujan J, Hernandez Q, Valero G, Parrilla P. Intragastric balloon reduces liver volume in superobese patients, facilitating subsequent laparoscopic gastric bypass. Obes Surg 2007;17:150-4.
52. Spyropoulos C, Katsakoulis E, Mead N, Vagenas K, Kalfarentzos F. Intragastric balloon for high-risk super-obese patients: a prospective analysis of efficacy. Surg Obes Relat Dis 2007;3:78-83.
53. Angrisani L, Lorenzo M, Borrelli V, Giuffre M, Fonderico C, Capece G. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg 2006;16:1135-7.
54. Melissas J, Mouzas J, Filis D, Daskalakis M, Matrella E, Papadakis JA, et al. The intragastric balloon - smoothing the path to bariatric surgery. Obes Surg 2006;16:897-902.
55. Loffredo A, Cappucci M, De Luca M, de Werra C, Galloro G, Naddeo M, et al. Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg 2001;11:330-3.
56. de Goederen-van der Meij S, Pierik RG, Oudkerk PM, Gouma DJ, Mathus-Vliegen LM. Six months of balloon treatment does not predict the success of gastric banding. Obes Surg 2007;17:88-94.
57. Genco A, Lorenzo M, Baglio G, Furbetta F, Rossi A, Lucchese M, et al. Does the intragastric balloon have a predictive role in subsequent LAP-BAND surgery? Italian multicenter study results at 5-year follow-up. Surg Obes Relat Dis 2013. http://dx.doi.org/10.1016/j.soard.2013.10.021.
58. Dumonceau JM, Francois E, Hittelet A, Mehdi AI, Barea M, Deviere J. Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study. Obes Surg 2010;20:692-7.
59. Lopez-Nava G, Rubio MA, Prados S, Pastor G, Cruz MR, Companioni E, et al. BioEnterics(R) intragastric balloon (BIB(R)). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg 2011;21:5-9.
60. Genco A, Cipriano M, Bacci V, Maselli R, Paone E, Lorenzo M, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg 2010;20:1496-500.
61. Genco A, Maselli R, Frangella F, Cipriano M, Paone E, Meuti V, et al. Effect of consecutive intragastric balloon (BIB(R)) plus diet versus single BIB(R) plus diet on eating disorders not otherwise specified (EDNOS) in obese patients. Obes Surg 2013;23:2075-9.
62. Genco A, Lopez-Nava G, Wahlen C, Maselli R, Cipriano M, Sanchez MM, et al. Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes Surg 2013;23:515-21.
63. De Castro ML, Morales MJ, Del Campo V, Pineda JR, Pena E, Sierra JM, et al. Efficacy, safety, and tolerance of two types of intragastric balloons placed in obese subjects: a double-blind comparative study. Obes Surg 2010;20: 1642-6.
64. Giardiello C, Borrelli A, Silvestri E, Antognozzi V, Iodice G, Lorenzo M. Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obes Surg 2012;22:1916-9.
65. Forestieri P, De Palma GD, Formato A, Giuliano ME, Monda A, Pilone V, et al. Heliosphere Bag in the treatment of severe obesity: preliminary experience. Obes Surg 2006;16:635-7.
66. Trande P, Mussetto A, Mirante VG, De ME, Olivetti G, Conigliaro RL, et al. Efficacy, tolerance and safety of new intragastric air-filled balloon (Heliosphere BAG) for obesity: the experience of 17 cases. Obes Surg 2010;20: 1227-30.
67. Lecumberri E, Krekshi W, Matia P, Hermida C, de la Torre NG, Cabrerizo L, et al. Effectiveness and safety of air-filled balloon Heliosphere Bag(R) in 82 consecutive obese patients. Obes Surg 2011;21:1508-12.
68. Genco A, Dellepiane D, Baglio G, Cappelletti F, Frangella F, Maselli R, et al. Adjustable intragastric balloon vs nonadjustable intragastric balloon: case-control study on complications, tolerance, and efficacy. Obes Surg 2013;23: 953-8.
69. Machytka E, Klvana P, Kornbluth A, Peikin S, Mathus-Vliegen LE, Gostout C, et al. Adjustable intragastric balloons: a 12- month pilot trial in endoscopic weight loss management. Obes Surg 2011;21:1499-507.
70. Brooks J, Srivastava ED, Mathus-Vliegen EM. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg 2014;24:813-9.
71. Carvalho GL, Barros CB, Okazaki M, Novaes ML, Albuquerque PC, Almeida NC, et al. An improved intragastric balloon procedure using a new balloon: preliminary analysis of safety and efficiency. Obes Surg 2009;19:237-42.
72. Carvalho GL, Barros CB, Moraes CE, Okazaki M, Ferreira MN, Silva JS, et al. The use of an improved intragastric balloon technique to reduce weight in pre-obese patientsepreliminary results. Obes Surg 2011;21:924-7.
73. Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating safety and efficacy of intragstrric dual-baloon in obesity. Surg Obes Rel Dis 2013;9:290-5.
74. Lopasso FP, Sakai P, Gazi BM, Artifon EL, Kfouri C, Souza JP, et al. A pilot study to evaluate the safety, tolerance, and efficacy of a novel stationary antral balloon (SAB) for obesity. J Clin Gastroenterol 2008;42:48-53.
75. Gaggiotti G, Tack J, Garrido Jr AB, Palau M, Cappelluti G, Di MF. Adjustable totally implantable intragastric prosthesis (ATIIP)-Endogast for treatment of morbid obesity: one-year follow-up of a multicenter prospective clinical survey. Obes Surg 2007;17:949-56.
76. Martin CK, Bellanger DE, Rau KK, Coulon S, Greenway FL. Safety of the ullorex oral intragastric balloon for the treatment of obesity. J Diabetes Sci Technol 2007;1:574-81.
77. Mion F, Ibrahim M, Marjoux S, Ponchon T, Dugardeyn S, Roman S, et al. Swallowable Obalon gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg 2013;23:730-3.
78. de Jonge C, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, BuurmanWA, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg 2013;23:1354-60.
79. de Jonge C, Rensen SS, D'Agnolo HM, Bouvy ND, BuurmanWA, Greve JW. Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetes. Obes Surg 2014;24:337-41.
80. Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis 2008;4:55-9.
81. de Moura EG, Orso IR, Martins BC, Lopes GS, de Oliveira SL, Galvao-Neto MP, et al. Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. Obes Surg 2011;21:941-7.
82. de Moura EG, Martins BC, Lopes GS, Orso IR, de Oliveira SL, Galvao Neto MP, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther 2012;14:183-9.
83. Escalona A, Yanez R, Pimentel F, Galvao M, Ramos AC, Turiel D, et al. Initial human experience with restrictive duodenal-jejunal bypass liner for treatment of morbid obesity. Surg Obes Relat Dis 2010;6:126-31.
84. Escalona A, Pimentel F, Sharp A, Becerra P, Slako M, Turiel D, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg 2012;255: 1080-5.
85. Cohen RV, Neto MG, Correa JL, Sakai P, Martins B, Schiavon CA, et al. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab 2013;98:E279-82.
86. Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther 2009;11:725-32.
87. Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc 2010;71:976-82.
88. Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 2010;251: 236-43.
89. Tarnoff M, Rodriguez L, Escalona A, Ramos A, Neto M, Alamo M, et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc 2009;23:650-6.
90. Zechmeister-Koss I, Huic M, Fischer S. The duodenal-jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review. Obes Surg 2014;24:310-23.
91. Patel SR, Mason J, Hakim N. The duodenal-jejunal bypass sleeve (EndoBarrier gastrointestinal liner) for weight loss and treatment of type II diabetes. Indian J Surg 2012;74:275-7.
92. Patel SR, Hakim D, Mason J, Hakim N. The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes. Surg Obes Relat Dis 2013;9:482-4.
93. Rohde U, Hedback N, Gluud LL, Vilsboll T, Knop FK. Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies. BMJ Open 2013;3:e003417.
94. Mathus-Vliegen EM. Endobarrier: a unique but still premature concept. Ned Tijdschr Geneeskd 2012;156:A4590.
95. Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodeno-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multi-center randomized controlled trial. Ann Surg 2014 [accepted].
96. Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 2011;25:3028-33.
97. Garcia-Compean D, Maldonado GH. Intragastric injection of botulinum toxin for the treatment of obesity. Where are we? World J Gastroenterol 2008;14:1805-9.
98. Sauer N, Rosch T, Pezold J, Reining F, Anders M, Groth S, et al. A new endoscopically implantable device (SatiSphere) for treatment of obesityeefficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes Surg 2013; 23:1727-33.
99. Sullivan S, Stein R, Jonnalagadda S, Mullady D, Edmundowicz S. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013;145:1245-52.
100. Devault KR. Could aspiration therapy for obesity be an effective and safe alternative to traditional bariatric surgery? Gastroenterology 2013;145:1188-90.
101. Fogel R, De FJ, Bonilla Y, De La Fuente R. Clinical experience of transoral suturing for an endoluminal vertical gastroplasty: 1-year follow-up in 64 patients. Gastrointest Endosc 2008;68:51-8.
102. Brethauer SA, Chand B, Schauer PR, Thompson CC. Transoral gastric volume reduction for weight management: technique and feasibility in 18 patients. Surg Obes Relat Dis 2010;6:689-94.
103. Brethauer SA, Chand B, Schauer PR, Thompson CC. Transoral gastric volume reduction as intervention for weight management: 12-month follow-up of TRIM trial. Surg Obes Relat Dis 2012;8:296-303.
104. Espinos JC, Turro R, Mata A, Cruz M, da CM, Villa V, et al. Early experience with the Incisionless Operating Platform (IOP) for the treatment of obesity: the Primary Obesity Surgery Endolumenal (POSE) procedure. Obes Surg 2013;23: 1375-83.
105. Deviere J, Ojeda VG, Cuevas HL, Closset J, Le MO, Eisendrath P, et al. Safety, feasibility and weight loss after transoral gastroplasty: first human multicenter study. Surg Endosc 2008;22:589-98.
106. Moreno C, Closset J, Dugardeyn S, Barea M, Mehdi A, Collignon L, et al. Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study. Endoscopy 2008; 40:406-13.
107. Familiari P, Costamagna G, Blero D, Le MO, Perri V, Boskoski I, et al. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome. Gastrointest Endosc 2011;74:1248-58.
108. Biertho L, Hould FS, Lebel S, Biron S. Transoral endoscopic restrictive implant system: a new endoscopic technique for the treatment of obesity. Surg Obes Relat Dis 2010;6:203-5.
109. de Jong K, Mathus-Vliegen EM, Veldhuyzen EA, Eshuis JH, Fockens P. Short-term safety and efficacy of the Trans-oral Endoscopic Restrictive Implant System for the treatment of obesity. Gastrointest Endosc 2010;72:497-504.
110. Verlaan T, Paulus GF, Mathus-Vliegen EMH, Veldhuyzen EAML, Conchillo JM, Bouvy ND, et al. Endoscopic gastric volume reduction with a novel articulating plication device is safe and effective in the treatment of obesity. Gastrointest Endosc 2014 [accepted].